Immunohistochemical profile of ING3 protein in normal and cancerous tissues.
Immunohistochemical profile of ING3 protein in normal and cancerous tissues.
复制标题
正常组织和癌组织中 ING3 蛋白的免疫组织化学特征
DOI：
10.3892/ol.2017.5632
复制
发表时间：
2017-03
期刊：
影响因子：
2.9
通讯作者：
Zheng HC
中科院分区：
文献类型：
--
作者：
Gou WF;Yang XF;Shen DF;Zhao S;Sun HZ;Luo JS;Zheng HC
生长家族抑制剂成员3 （ING3）蛋白可能通过激活p53-反激活的p21启动子和bcl2相关的X蛋白来阻断细胞周期，并可能通过Fas/caspase-8依赖的信号通路诱导细胞凋亡。本研究采用免疫组化方法，对ING3蛋白在小鼠和人正常组织、人肝细胞（n=62）、肾透明细胞（n=62）、胰腺（n=62）、食管鳞状细胞（n=45）、宫颈鳞状细胞（n=31）、乳腺（n=144）、胃（n=196）、结直肠（n=96）、卵巢（n=208）、子宫内膜（n=96）和肺癌（n=192）组织微阵列中的表达谱进行了表征。在小鼠组织中，ING3蛋白在心肌细胞、肾脏和骨骼肌细胞的细胞质中阳性检测，在支气管和肺泡上皮、胃和肠腺以及乳腺细胞的细胞质和细胞核中也检测到。在人体组织中，ING3蛋白主要分布在细胞质中，但在舌、食管、胃、肠、肺、皮肤、阑尾、膀胱、子宫颈和乳腺细胞的细胞质和细胞核中均有发现。ING3免疫反应性在胃、皮肤和颈部组织中检测到较强，而在小脑、脑干、胸腺、肝脏、骨骼肌、睾丸和前列腺组织中检测到较弱的信号。在1194个被检测的癌症实体中，总共有424个（35.5%）发现了ing3阳性标本。在许多病例中，观察到ING3的表达仅限于细胞质和细胞核，不包括乳腺癌和肝细胞癌的细胞质分布。在这些病例中，ING3在乳腺和妇科类型的癌症中表达频率更高，包括卵巢癌（59.2%）、子宫内膜癌（47.9%）、乳腺癌（38.9%）和宫颈癌（35.5%）。ing3阳性在肾透明细胞癌（17.7%）、肝细胞癌（16.1%）和食管癌（17.8%）中较为少见。提示ING3可能参与器官或组织的修复和再生，并可能与妇科癌变密切相关。
The inhibitor of growth family, member 3 (ING3) protein may be capable of blocking the cell cycle via activating p53-transactivated promoters of p21 and Bcl2-associated X protein, and may induce apoptosis via a Fas/caspase-8-dependent signaling pathway. In the present study, immunohistochemistry was performed in order to characterize the expression profile of ING3 protein in tissue microarrays containing mouse and human normal tissue, human hepatocellular (n=62), renal clear cell (n=62), pancreatic (n=62), esophageal squamous cell (n=45), cervical squamous cell (n=31), breast (n=144), gastric (n=196), colorectal (n=96), ovarian (n=208), endometrial (n=96) and lung carcinoma (n=192). In mouse tissue, ING3 protein was positively detected in the cytoplasm of cardiomyocytes, kidney and skeletal muscle cells, and was additionally detected in the cytoplasm and nucleus of bronchial and alveolar epithelium, gastric and intestinal gland, and mammary gland cells. In human tissues, ING3 protein was principally distributed in the cytoplasm, but was observed in the cytoplasm and nucleus of tongue, esophagus, stomach, intestine, lung, skin, appendix, bladder, cervix and breast cells. ING3 immunoreactivity was strongly detected in the stomach, skin and cervical tissues, whereas a weak signal was detected in the cerebellum, brain stem, thymus, liver, skeletal muscle, testis and prostate. In total, ING3-positive specimens were identified in 424 of 1,194 tested cancer entities (35.5%). In a number of cases, ING3 expression was observed to be restricted to the cytoplasm and nucleus, excluding the cytoplasmic distribution identified in breast and hepatocellular carcinoma. Among these cases, ING3 was more frequently expressed in breast and gynecological types of cancer, including ovarian (59.2%), endometrial (47.9%), breast (38.9%) and cervical (35.5%) cancer. ING3-positive cases were more rare in renal clear cell (17.7%), hepatocellular (16.1%) and esophageal carcinoma (17.8%). It is suggested that ING3 may be involved in the repair and regeneration of organs or tissues, and may be closely associated with gynecological carcinogenesis.